Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles

被引:41
|
作者
Vaccari, Sergio
Latini, Stefania
Barberi, Marzia
Teti, Anna
Stefanini, Mario
Canipari, Rita
机构
[1] Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy
[2] Univ Laquila, Dept Expt Med, Rome, Italy
关键词
MESSENGER-RIBONUCLEIC-ACID; GRANULOSA-CELLS; PLASMINOGEN-ACTIVATOR; HYPOTHALAMIC PEPTIDE; MOUSE OOCYTES; IN-VITRO; PACAP; VIP; RADIOIMMUNOASSAY; STEROIDOGENESIS;
D O I
10.1677/joe.1.06470
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a bioactive peptide transiently expressed in preovulatory follicles. PACAP acts by interacting with three types of PACAP receptors. PACAP type I receptor (PAC(1)-R), which binds specifically to both PACAPs and vasoactive intestinal polypeptide (VIP), although with lower affinity, and two VIP receptors, VPAC(1)-R and VPAC(2)-R, which bind to PACAP and VIP with equal affinity. In the present study, we showed the expression of all three receptors in whole ovaries obtained from juvenile and gonadotropin-treated immature rats. A more detailed analysis on cells from preovulatory follicles showed that PAC1-R and VPAC2-R were expressed in granulosa cells, whereas only VIP receptors were expressed in theca/interstitial (TI) cells and fully grown oocytes presented only PAC(1)-R. The distribution of the VIP receptors was confirmed by immunofluorescence. HCG treatment induced stimulation of PAC(1)-R in granulosa cells and VPAC2-R in TI cells. The presence of functional PACAP/VIP receptors was also supported by metabolic studies. We further evaluated the presence of PACAP and VIP receptors by testing the effect of these peptides on apoptosis in granulosa cells cultured, isolated or in whole follicles. Treatment of follicles with PACAP and VIP dose-dependently inhibited apoptosis, while only PACAP significantly inhibited isolated granulosa cells. These results demonstrate a different expression of PACAP/VIP receptors in the various follicle compartments and suggest a possible role for PACAP and VIP on granulosa and TI cells, both during follicle development and ovulation.
引用
收藏
页码:287 / 299
页数:13
相关论文
共 50 条
  • [21] Effects of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide, and somatostatin on the release of thyrotropin from the bullfrog pituitary
    Okada, Reiko
    Yamamoto, Kazutoshi
    Ito, Yoichi
    Chartrel, Nicolas
    Leprince, Jerome
    Fournier, Alain
    Vaudry, Hubert
    Kikuyama, Sakae
    VIP, PACAP, AND RELATED PEPTIDES: FROM GENE TO THERAPY, 2006, 1070 : 474 - 480
  • [22] POSSIBLE INVOLVEMENT OF VASOACTIVE INTESTINAL POLYPEPTIDE IN THE CENTRAL STIMULATING ACTION OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE ON PROLACTIN SECRETION IN THE RAT
    YAMAUCHI, K
    MURAKAMI, Y
    NISHIKI, M
    TANAKA, J
    KOSHIMURA, K
    KATO, Y
    NEUROSCIENCE LETTERS, 1995, 189 (02) : 131 - 134
  • [23] Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation
    Hashimoto, H
    Ogawa, N
    Hagihara, N
    Yamamoto, K
    Imanishi, K
    Nogi, H
    Nishino, A
    Fujita, T
    Matsuda, T
    Nagata, S
    Baba, A
    MOLECULAR PHARMACOLOGY, 1997, 52 (01) : 128 - 135
  • [24] Effect of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on mouse preantral follicle development in vitro
    Cecconi, S
    Rossi, G
    Barberi, M
    Scaldaferri, L
    Canipari, R
    ENDOCRINOLOGY, 2004, 145 (04) : 2071 - 2079
  • [25] Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide(1), and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide vasoactive intestinal peptide(1) receptors: Evidence for multiple receptor states
    VanRampelbergh, J
    Gourlet, P
    DeNeef, P
    Robberecht, P
    Waelbroeck, M
    MOLECULAR PHARMACOLOGY, 1996, 50 (06) : 1596 - 1604
  • [26] REGIONAL HEMODYNAMIC-RESPONSES TO PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE AND VASOACTIVE INTESTINAL POLYPEPTIDE IN CONSCIOUS RATS
    GARDINER, SM
    RAKHIT, T
    KEMP, PA
    MARCH, JE
    BENNETT, T
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (02) : 589 - 597
  • [27] Regulation of feeding behavior by pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) in vertebrates
    Matsuda, Kouhei
    Maruyama, Keisuke
    PEPTIDES, 2007, 28 (09) : 1761 - 1766
  • [28] Pituitary adenylate cyclase-activating polypeptide and its receptors in amphibians
    Yon, L
    Alexandre, D
    Montéro, M
    Chartrel, N
    Jeandel, L
    Vallarino, M
    Conlon, JM
    Kikuyama, S
    Fournier, A
    Gracia-Navarro, F
    Roubos, E
    Chow, B
    Arimura, A
    Anouar, Y
    Vaudry, H
    MICROSCOPY RESEARCH AND TECHNIQUE, 2001, 54 (03) : 137 - 157
  • [29] Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1
    Harmar, Anthony J.
    Fahrenkrug, Jan
    Gozes, Illana
    Laburthe, Marc
    May, Victor
    Pisegna, Joseph R.
    Vaudry, David
    Vaudry, Hubert
    Waschek, James A.
    Said, Sami I.
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (01) : 4 - 17
  • [30] Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors
    Bokaei, Payman Baradar
    Ma, Xue-Zhong
    Byczynski, Bartosz
    Keller, Jeremy
    Sakac, Darinka
    Fahim, Soad
    Branch, Donald R.
    GENOMICS, 2006, 88 (06) : 791 - 800